RCUS NYSE
Arcus Biosciences, Inc.
1W: -2.0%
1M: -18.1%
3M: -18.4%
YTD: +5.0%
1Y: +81.5%
3Y: +30.4%
5Y: -32.0%
$24.44
-0.79 (-3.13%)
Weekly Expected Move ±7.0%
$21
$23
$24
$26
$28
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships7
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-11-18
Earliest Filing
2024-08-27
Latest Filing
partner: 5
investor: 1
customer: 1
Counterparties (Filed by RCUS)
7 relationshipsCompanies named in RCUS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | partner | Holder of an option on certain assets securing the loan. | 2024-08-27 | View |
| Taiho Pharmaceutical Co., Ltd. | — | partner | Holder of an option on certain assets securing the loan. | 2024-08-27 | View |
| Gilead Sciences, Inc. | GILD | investor | Purchased 15.2M shares in a financing round and appointed a director to the board. | 2024-01-30 | View |
| Gilead Sciences, Inc. | GILD | customer | Gilead agreed to purchase 1,010,000 shares of Arcus common stock at $19.26 per share under an amended stock purchase agr | 2023-06-28 | View |
| Gilead Sciences, Inc. | GILD | partner | Amendment to Option, License and Collaboration Agreement for inflammatory disease research programs | 2023-05-15 | View |
| Gilead Science, Inc. | GILD | partner | Extended lock-up restrictions under Investor Rights Agreement | 2022-10-11 | View |
| Gilead Sciences, Inc. | GILD | partner | Amendment to Option, License and Collaboration Agreement involving option exercise for three programs and co-development | 2021-11-18 | View |
Mentioned As Counterparty
1 mentionsOther companies that named RCUS in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-06-12 | Shareholder Vote | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-20 | Other Events | View | |
| 2026-03-23 | Officer/Director Change | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-18 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2025-12-12 | Other Events | View | |
| 2025-11-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Other Events | View | |
| 2025-10-06 | Other Events | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-12 | Submission of Matters to a Vote of Security Holders; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-02 | Regulation FD Disclosure; Other Events | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-18 | Results of Operations and Financial Condition; Other Events | View | |
| 2025-02-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-01-21 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR